Ironwood expects LINZESS to exceed $1B in 2021 US net sales; raises 2021 adjusted EBITDA guidance to >$230M

IRONWOOD PHARMACEUTICALS INC

2021-FY EPS reported $3.21 revenue$413,753,000

LINZESS U.S. net sales expected to surpass $1B in 2021, achieving blockbuster status.
2021 guidance updated: LINZESS growth at high end of 6-8%; total revenue high end of $390-410M.
Adjusted EBITDA guidance raised to >$230M (from >$210M) for 2021.
2022 guidance: LINZESS low single-digit growth; total revenue $420-430M; adjusted EBITDA >$250M.
Board authorized $150M share repurchase; $27M repurchased in Q4 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.